Danaher (NYSE:DHR) Reaches New 52-Week Low After Analyst Downgrade

Shares of Danaher Corporation (NYSE:DHR) reached a new 52-week low during mid-day trading on Thursday after Morgan Stanley lowered their price target on the stock from $270.00 to $255.00. The company traded as low as $176.60 and last traded at $176.3780, with a volume of 1155776 shares traded. The stock had previously closed at $184.04.

A number of other research firms have also recently weighed in on DHR. Leerink Partners boosted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. JPMorgan Chase & Co. cut their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday. KeyCorp restated an “overweight” rating on shares of Danaher in a research report on Thursday, January 29th. Robert W. Baird lowered their target price on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, UBS Group cut their price target on Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Wednesday. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $242.45.

Insider Buying and Selling

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the sale, the executive vice president owned 5,099 shares in the company, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 10.80% of the company’s stock.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight full‑year EPS raise: Danaher reported $2.06 non‑GAAP EPS (ahead of estimates) and nudged FY‑2026 adjusted EPS guidance to a range that was only modestly higher, supporting the view of durable profitability. Read More.
• Positive Sentiment: Analyst support from Evercore: Evercore raised its price target (to $232) and maintained an outperform stance, providing some buy‑side reinforcement amid the downdraft. Read More.
• Neutral Sentiment: Large euro‑note offering announced: Danaher priced ~€3.0B net of proceeds in four tranches (2028–2038 maturities). The deal boosts liquidity but increases gross debt on the balance sheet while funding corporate needs (including M&A). Read More.
• Neutral Sentiment: Bioprocessing strength vs. mixed start: Management highlighted bioprocessing momentum and acquisition strategy, which helped headline growth, but the quarter showed mixed signals across segments. Read More.
• Negative Sentiment: Revenue miss and Diagnostics softness: Revenue rose ~3.7% Y/Y but missed consensus; core revenue growth was modest and Diagnostics saw weakness (lighter respiratory season at Cepheid), which worried investors despite the EPS beat. Read More.
• Negative Sentiment: Multiple price‑target cuts: Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), which can prompt headline selling and reduce near‑term upside expectations. Read More. Read More. Read More.
• Negative Sentiment: Market concern about Masimo deal & capital allocation: Commentators flagged near‑term uncertainty around integration, capital allocation and how incremental spending/financing (including the euro notes) will affect returns, adding to investor caution. Read More.
• Negative Sentiment: Insider selling & repositioning by institutions: Reports of recent insider sales and large institutional rebalancing were cited in market coverage, which may have amplified downward pressure. Read More.

Institutional Trading of Danaher

Several institutional investors have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new position in Danaher during the 3rd quarter worth approximately $25,000. Elevated Capital Advisors LLC bought a new stake in shares of Danaher in the 4th quarter valued at $26,000. WFA of San Diego LLC acquired a new stake in shares of Danaher during the second quarter worth $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Danaher during the third quarter worth $27,000. Finally, Hilton Head Capital Partners LLC bought a new position in Danaher during the fourth quarter worth $27,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

The firm has a market cap of $125.52 billion, a P/E ratio of 34.13, a P/E/G ratio of 2.64 and a beta of 0.95. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average is $197.17 and its two-hundred day moving average is $214.35.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.96% and a net margin of 14.89%.The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period last year, the business posted $1.88 EPS. The business’s revenue was up 3.7% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, analysts anticipate that Danaher Corporation will post 8.39 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be paid a dividend of $0.40 per share. This is an increase from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s payout ratio is 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.